Oncimmune (LON:ONC) Shares Down 13.3% – Should You Sell?

Oncimmune Holdings plc (LON:ONCGet Free Report) shares were down 13.3% during trading on Friday . The stock traded as low as GBX 8.55 ($0.11) and last traded at GBX 10.80 ($0.13). Approximately 884,827 shares changed hands during mid-day trading, an increase of 240% from the average daily volume of 259,890 shares. The stock had previously closed at GBX 12.45 ($0.15).

Oncimmune Stock Down 25.1 %

The company has a fifty day moving average of GBX 14.22 and a 200 day moving average of GBX 14.85. The company has a quick ratio of 0.63, a current ratio of 1.13 and a debt-to-equity ratio of 806.85. The company has a market cap of £6.91 million, a P/E ratio of -310.83 and a beta of 1.19.

About Oncimmune

(Get Free Report)

Oncimmune Holdings plc, an immunodiagnostics company, develops solutions for immuno-oncology, autoimmune disease and infectious diseases in the United Kingdom, North America, Europe, and internationally. It offers EarlyCDT-Lung, an immunodiagnostic blood test for detecting and identifying lung cancer; ImmunoINSIGHTS that enables life science organizations to optimize drug development and delivery; SeroTag discovery arrays for discovering and validating biomarkers for stratifying patients in multiple cancer indications, infectious diseases, and with various autoimmune diseases; and NavigAID, a disease-specific characterization panel.

Featured Stories

Receive News & Ratings for Oncimmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncimmune and related companies with MarketBeat.com's FREE daily email newsletter.